Last update Jan. 6, 2021
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Solifenacin Succinate in other languages or writings:
Solifenacin Succinate belongs to this group or family:
Main tradenames from several countries containing Solifenacin Succinate in its composition:
|Protein Binding||93 - 98||%|
|Tmax||3 - 8||hours|
|T½||33 - 85||hours|
Write us at firstname.lastname@example.org
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Anticholinergic and antimuscarinic drug that acts in a similar fashion to atropin.
Prescribed for the treatment of symptoms related to hyperactive bladder.
Administered orally once a day.
We did not find published data regarding the excretion of this substance through breast milk at the time this last update was completed.
Due to its pharmacokinetic data (large distribution volume, moderately high molecular weight and high protein binding percentage: Astellas 2020, AEMPS 2018)
it is very unlikely for any significant amounts to pass into human milk, even though its long elimination half-life would facilitate it.
This drug is approved by the FDA for use by pediatric patients older than two years of age (Astellas 2020).
Expert authors regard this medication as probably safe to use during lactation. (Briggs 2017).
Anticholinergic drugs tend to decrease milk production therefore it is important to monitor milk production.
Be on the lookout for any signs of anticholinergic symptoms (dry mouth, constipation) on the breastfeeding child.
Until more published data regarding the interactions of this drug and breastfeeding is made available, it would be preferable the use of an alternative with a safer pharmacokinetic profile for lactation (with shorter elimination half-life and lower oral bioavailability), especially during the neonatal period or in the event of prematurity.